90 results on '"Mäkisalo, Heikki"'
Search Results
2. High immune cell infiltration predicts improved survival in cholangiocarcinoma.
- Author
-
Wirta EV, Szeto S, Koppatz H, Nordin A, Mäkisalo H, Arola J, Sirén J, Ahtiainen M, Böhm J, Mecklin JP, Sallinen V, and Seppälä TT
- Abstract
Background: Antitumoral immune response has a crucial role in constraining cancer. However, previous studies on cholangiocarcinoma (CCA), a rare and aggressive cancer, have reported contradictory findings on the prognostic impact of tumor-infiltrating T-lymphocytes. We aimed to clarify the effect of tumor-infiltrating CD3+ and CD8+ lymphocytes and PD-1/PD-L1 expression on CCA prognosis., Methods: CD3+, CD8+, and PD-1+ lymphocyte densities, as well as PD-L1 expression rate were analyzed from stained tissue microarray samples from the tumor center and invasive margin of 47 cholangiocarcinomas. The association of CD3+ and CD8+ based Immune cell score (ICS) and its components with overall survival was evaluated, adjusting for age, sex, TNM stage, radicality of surgery, tumor location, and PD-L1 expression on immune cells., Results: Low ICS was a strong independent prognostic factor for worse overall survival (Hazard ratio 9.27, 95% confidence interval 2.72-31.64, P<0.001). Among the ICS components, high CD8+ lymphocyte infiltration at the tumor center had the most evident impact on patient outcome. PD-1 and PD-L1 expression on immune cells did not have a significant impact on overall survival alone; however, PD-L1 positivity seemed to impair survival for ICS
low subgroup., Conclusion: Identifying patient subgroups that could benefit from immunotherapy with PD-1/PD-L1 pathway blockade may help improve treatment strategies for this aggressive cancer. Our findings highlight the importance of evaluating the immune contexture in cholangiocarcinoma, as ICS serves as a strong independent prognostic and selective factor for patients who might benefit from immunotherapy., Competing Interests: TS reports a consultation fee from Amgen Finland, and being a co-owner and CEO of Healthfund Finland Ltd, and the Clinical Advisory Board of LS Cancer Diag Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Wirta, Szeto, Koppatz, Nordin, Mäkisalo, Arola, Sirén, Ahtiainen, Böhm, Mecklin, Sallinen and Seppälä.)- Published
- 2024
- Full Text
- View/download PDF
3. NGS of brush cytology samples improves the detection of high-grade dysplasia and cholangiocarcinoma in patients with primary sclerosing cholangitis: A retrospective and prospective study.
- Author
-
Boyd S, Mustamäki T, Sjöblom N, Nordin A, Tenca A, Jokelainen K, Rantapero T, Liuksiala T, Lahtinen L, Kuopio T, Kytölä S, Mäkisalo H, Färkkilä M, and Arola J
- Subjects
- Humans, Retrospective Studies, Prospective Studies, Proto-Oncogene Proteins p21(ras) genetics, Cholangiopancreatography, Endoscopic Retrograde adverse effects, Bile Ducts, Intrahepatic, High-Throughput Nucleotide Sequencing, Cholangitis, Sclerosing complications, Cholangitis, Sclerosing diagnosis, Cholangitis, Sclerosing genetics, Bile Duct Neoplasms diagnosis, Bile Duct Neoplasms genetics, Cholangiocarcinoma diagnosis, Cholangiocarcinoma genetics
- Abstract
Background: Biliary dysplasia, a precursor of cholangiocarcinoma (CCA), is a common complication of primary sclerosing cholangitis. Patients with high-grade dysplasia (HGD) or early CCA who have received oncological treatment are candidates for liver transplantation. The preoperative diagnosis of CCA or HGD is challenging, and the sensitivity of biliary brush cytology (BC) is limited., Methods: By using next-generation sequencing (NGS), we retrospectively analyzed archived tissue samples (n=62) obtained from explanted liver tissue and CCA samples to identify oncogenic mutations that occur during primary sclerosing cholangitis carcinogenesis. BC samples were prospectively collected from patients with primary sclerosing cholangitis (n=97) referred for endoscopic retrograde cholangiography to measure the diagnostic utility of NGS combined with BC compared with traditional cytology alone., Results: Mutations in KRAS, GNAS, FLT3, RNF43, TP53, ATRX, and SMAD4 were detected in archived CCA or HGD samples. KRAS, GNAS, TP53, CDKN2A, FBXW7, BRAF, and ATM mutations were detected in prospectively collected brush samples from patients with histologically verified CCA or HGD. One patient with low-grade dysplasia in the explanted liver had KRAS and GNAS mutations in brush sample. No mutations were observed in brush samples or archived tissues in liver transplantation cases without biliary neoplasia. While KRAS mutations are common in biliary neoplasms, they were also observed in patients without biliary neoplasia during surveillance., Conclusions: In summary, NGS of BC samples increased the sensitivity of detecting biliary neoplasia compared with traditional cytology. Performing NGS on BC samples may help diagnose HGD or early CCA, benefiting the timing of liver transplantation., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.)
- Published
- 2024
- Full Text
- View/download PDF
4. The first 10 years of simultaneous pancreas-kidney transplantation in Finland.
- Author
-
Ahopelto K, Sallinen V, Helanterä I, Bonsdorff A, Grasberger J, Beilmann-Lehtonen I, Mäkisalo H, Nordin A, Ortiz F, Savikko J, Tukiainen E, Uutela A, Ekstrand A, and Lempinen M
- Subjects
- Humans, Finland, Retrospective Studies, Treatment Outcome, Graft Survival, Kidney Transplantation adverse effects, Diabetes Mellitus, Type 1 complications, Pancreas Transplantation adverse effects
- Abstract
Introduction: Simultaneous pancreas-kidney transplantation (SPK) is an option for patients with type 1 diabetes (T1D) and kidney failure but can be associated with a high complication rate. Here we describe our 10-year experience since the launch of the SPK program., Methods: This retrospective study included consecutive patients with T1D receiving SPK from March 14, 2010 to March 14, 2020 at Helsinki University Hospital. Portocaval anastomosis (i.e., systemic venous drainage) and enteric exocrine drainage were used. A specific team was trained for both pancreas retrieval and transplantation, postoperative care was standardized to include somatostatin analogues, antimicrobial treatment, and preoperatively initiated chemothrombopropylaxis. During program maturation donor criteria were expanded and logistical processes improved to minimize cold ischemia time. Clinical data were collected from a nationwide transplantation registry and patient records., Results: A total of 166 SPKs were performed (median 2 per year in the first 3 years, 17.5 per year for the following 4 years, and 23 per year for the past 3 years). Seven patients (4.1%) died with a functioning graft with a median 43 months follow-up. One-year pancreas graft survival was 97.0%, 3-year pancreas graft survival was 96.1% and 5-year was 96.1%. Mean HbA1c was 36 mmol/mol (SD 5.57) and creatinine was 107 μmol/L (SD 34.69) at 1-year after transplantation. All kidney grafts were functioning at the end of follow-up. Complications required re-laparotomy in 39 (23%) patients, mostly due to a pancreas graft related problem (N = 28). No pancreas or kidney graft failure from thrombosis occurred., Conclusion: A planned, step-wise development of an SPK program offers a safe and effective treatment for patients with T1D and kidney failure., (© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
5. Characteristics, management and outcomes of choledochal malformations in Finnish adult patients.
- Author
-
Hyvärinen I, Hukkinen M, Kivisaari R, Kylänpää L, Nordin A, Mäkisalo H, and Pakarinen MP
- Subjects
- Humans, Adult, Finland epidemiology, Common Bile Duct, Postoperative Complications epidemiology, Postoperative Complications etiology, Choledochal Cyst surgery, Choledochal Cyst complications
- Abstract
Conclusions: Nearly half of operated patients developed long-term postoperative complications. A novel association between CMs and IBD was observed. Although no hepatobiliary malignancies regardless of treatment modality were encountered, the number of patients and length of follow-up remained limited.
- Published
- 2023
- Full Text
- View/download PDF
6. Potential for intestinal transplantation after acute mesenteric ischemia in patients aged less than 70 years: A population-based study.
- Author
-
Lemma A, Pikkarainen S, Pohju A, Tolonen M, Mentula P, Vikatmaa P, Leppäniemi A, Mäkisalo H, and Sallinen V
- Subjects
- Humans, Retrospective Studies, Intestine, Small surgery, Necrosis etiology, Mesenteric Ischemia surgery, Mesenteric Ischemia complications, Short Bowel Syndrome surgery, Short Bowel Syndrome complications
- Abstract
Background and Objective: Acute mesenteric ischemia (AMI) has a high mortality rate due to the development of bowel necrosis. Patients are often ruled outside active care if a large proportion of small bowel is necrotic. With the development of treatment for short bowel syndrome (SBS) and intestinal transplantation methods, long-term survival is possible even after extensive small bowel resections. This study aims to assess the incidence of SBS and potentially suitable candidates for intestinal transplantation among patients treated for AMI., Methods: This population-based retrospective study comprised patients aged less than 70 years and diagnosed with AMI between January 2006 and October 2020 in Helsinki and Uusimaa health care district, Finland., Results: Altogether, AMI was diagnosed in 711 patients, of whom 133 (19%) were aged below 70. An intervention was performed in 110 (83%) patients. Of these 133 patients, 16 (12%) were ruled outside active treatment due to extensive small bowel necrosis at exploratory laparotomy, of whom 6 (5%) were potentially suitable for intestinal transplantation. Two patients were considered as potential candidates for intestinal transplantation at bowel resection but died of AMI. Nine (7%) patients needed parenteral nutrition after resection, and two of them (2%) developed SBS. Only one patient needed long-term parenteral nutrition after hospital discharge. This patient remained dependent on parenteral nutrition but died before evaluation of intestinal transplantation could be carried out while the other patient was able to return to enteral nutrition., Conclusions: A small number of patients with AMI below 70 years of age are potentially eligible for intestinal transplantation.
- Published
- 2023
- Full Text
- View/download PDF
7. Gamma-glutamyltransferase predicts macrovesicular liver graft steatosis - an analysis of discarded liver allografts in Finland.
- Author
-
Savikko J, Åberg F, Tukiainen E, Nordin A, Mäkisalo H, Arola J, and Isoniemi H
- Subjects
- Humans, Allografts, Finland epidemiology, gamma-Glutamyltransferase, Living Donors, Liver Transplantation, Non-alcoholic Fatty Liver Disease
- Abstract
Objective: Liver-transplantation activity is limited by the shortage of grafts. Donor-liver macrovesicular steatosis predisposes to ischemia-reperfusion injury and is associated with reduced graft survival. The increasing prevalence of fatty-liver disease underlines the importance of identifying macrovesicular steatosis in potential donor livers. We analyzed liver grafts discarded for transplantation, and particularly the role of gamma-glutamyltransferase (GGT) in predicting graft steatosis., Methods: One-hundred sixty rejected cadaveric-donor liver grafts were studied. Donor selection was based on clinical data, and macroscopic graft inspection. Discarded grafts were biopsied at procurement of non-liver organs., Results: The most common reasons for discarding the graft were abnormal liver tests, ultrasound-verified steatosis and history of harmful alcohol use. GGT correlated moderately with macrovesicular steatosis ( r = 0.52, p < 0.001), but poorly with microvesicular steatosis ( r = 0.36, p < 0.001). Increased correlation between GGT and macrovesicular steatosis was observed among alcohol abusers ( r = 0.67, p < 0.001). Area under the curve (AUC) of GGT for predicting >30% macrovesicular steatosis was 0.79 (95% CI 0.71-0.88), and for >60% steatosis, 0.79 (95% CI 0.68-0.90). The optimal GGT-cut off for detecting >30% and >60% macrovesicular steatosis were, respectively, 66 U/L (sensitivity 76% and specificity 68%) and 142 U/L (sensitivity 66% and specificity 83%). Among alcohol users, a GGT value >90 U/L showed 100% sensitivity for >60% macrovesicular steatosis. AUC for GGT in predicting fibrosis Stages 2-4 was 0.82 (95% CI 0.71-0.92, p < 0.001, optimal cut off 68, sensitivity 92%, specificity 61%)., Conclusions: Abnormal liver values, steatosis and harmful alcohol use were the main reasons for discarding liver-graft offers in Finland. GGT proved useful in predicting moderate and severe liver graft macrovesicular steatosis.
- Published
- 2023
- Full Text
- View/download PDF
8. Timing of Organ Procurement From Brain-Dead Donors Associates With Short- and Long-Term Outcomes After Liver Transplantation.
- Author
-
Eerola V, Helanterä I, Åberg F, Lempinen M, Mäkisalo H, Nordin A, Isoniemi H, and Sallinen V
- Subjects
- Brain, Brain Death, Humans, Severity of Illness Index, End Stage Liver Disease, Liver Transplantation, Tissue and Organ Procurement
- Abstract
Brain death-induced cytokine storm is thought to harm transplantable organs. However, longer procurement times have been associated with non-inferior or better outcomes in kidney, heart, and lung transplants, while optimal procurement time for liver allografts is unknown. Our aim was to analyze the association of time interval from brain death to organ procurement with liver allograft outcomes in two nationwide cohorts. The association of procurement interval with graft survival and short-term complications was analysed in multivariable models. Altogether 643 and 58,017 orthotopic liver transplantations from brain-dead donors were included from Finland between June 2004 and December 2017 and the US between January 2008 and August 2018, respectively. Median time from brain death to organ procurement was 10.5 h in Finland and 34.6 h in the US. Longer interval associated with better graft survival (non-linearly, p = 0.016) and less acute rejections (OR 0.935 95% CI 0.894-0.978) in the US cohort, and better early allograft function ( p = 0.005; Beta -0.048 95% CI -0.085 -(-0.011)) in the Finnish cohort, in multivariable models adjusted with Donor Risk Index, recipient age, Model for End-Stage Liver Disease and indication for transplantation. Progressive liver injury after brain death is unlikely. Rushing to recover seems unnecessary; rest and repair might prove beneficial., Competing Interests: VE reports receiving funding from grants awarded to IH. VE reports receiving a grant from Munuaissäätiö (Finnish Kidney Association). VS reports receiving grants from Academy of Finland, Sigrid Juselius Foundation, Cancer Foundation Finland, Vatsatautien tutkimussäätiö Foundation and Mary and Georg Ehrnrooth's Foundation. IH reports receiving consulting fees from Novartis and Hansa Biopharma outside the submitted work. FÅ received research grants from Mary and Georg Ehrnrooth Foundation, Finska Läkaresällskapet, and Sigrid Jusélius Foundation outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Eerola, Helanterä, Åberg, Lempinen, Mäkisalo, Nordin, Isoniemi and Sallinen.)
- Published
- 2022
- Full Text
- View/download PDF
9. Response to Letter by Benson et al. on 'Hangover and the Effects of L-Cysteine'.
- Author
-
Eriksson CJP, Metsälä M, Möykkynen T, Mäkisalo H, Kärkkäinen O, Palmén M, Salminen JE, and Kauhanen J
- Subjects
- Alcohol Drinking, Humans, Alcoholic Intoxication, Cysteine
- Published
- 2021
- Full Text
- View/download PDF
10. Gallbladder cancer epidemiology, treatment and survival in Southern Finland - a population-based study.
- Author
-
Koppatz H, Takala S, Peltola K, But A, Mäkisalo H, Nordin A, and Sallinen V
- Subjects
- Finland epidemiology, Humans, Incidence, Neoplasm Staging, Retrospective Studies, Survival Rate, Carcinoma in Situ, Gallbladder Neoplasms epidemiology, Gallbladder Neoplasms pathology, Gallbladder Neoplasms therapy
- Abstract
Introduction: Gallbladder cancer (GBC) is a rare malignancy in Western population with poor prognosis. This study aimed to investigate the trends in GBC incidence, treatment pattern, and survival in Finland., Methods: Patients diagnosed with primary GBC in a geographically defined area (Southern Finland Regional Cancer Center) during 2006-2017 were identified., Results: Final cohort included 270 patients with GBC. The incidence was 1.32/100,000 persons, and it decreased 6.8 cases per million personyears during the study period. One hundred fifty-one (56%) patients were diagnosed at Stage IV. Fifty-one patients (19%) underwent curative-intent resection with 96% R0-resection rate. The median overall survival was 7.1 months and 5-year overall survival 11.6% for all patients, and 67.7 months and 56.8% after curative-intent resection, respectively. No improvement was noted over time in overall survival in patients with GBC, or in subgroups of different stages of GBC., Conclusions: The incidence of GBC is slightly decreasing in Southern Finland, but survival has not improved over time.
- Published
- 2021
- Full Text
- View/download PDF
11. Pre- vs. postoperative initiation of thromboprophylaxis in liver surgery.
- Author
-
Ainoa E, Uutela A, Nordin A, Mäkisalo H, and Sallinen V
- Subjects
- Anticoagulants adverse effects, Humans, Liver, Postoperative Complications etiology, Postoperative Complications prevention & control, Retrospective Studies, Pulmonary Embolism epidemiology, Pulmonary Embolism etiology, Pulmonary Embolism prevention & control, Venous Thromboembolism diagnosis, Venous Thromboembolism epidemiology, Venous Thromboembolism etiology
- Abstract
Background: Thromboprophylaxis protocols in liver surgery vary greatly worldwide. Due to limited research, there is no consensus whether the administration of thromboprophylaxis should be initiated pre- or postoperatively., Methods: Patients undergoing liver resection in Helsinki University Hospital between 2014 and 2017 were reviewed retrospectively. Initiation of thromboprophylaxis was changed in the institution in the beginning of 2016 from postoperative to preoperative. Patients were classified into two groups for analyses: thromboprophylaxis initiated preoperatively (Preop-group) or postoperatively (Postop-group). The incidences of VTE and haemorrhage within 30 days of surgery were compared between these groups. Patients with permanent anticoagulation were excluded., Results: A total of 512 patients were included to the study (Preop, n = 253, Postop, n = 259). The incidence of VTE was significantly lower in the Preop-group compared to the Postop-group (3 (1.2%) vs. 25 (9.7%), P = <.0001), mainly due to a lower incidence of pulmonary embolisms in the Preop-group (3 (1.2%) vs. 24 (9.3%), P < .0001). The rates of posthepatectomy haemorrhage within 30 days of surgery were similar (Preop 38 (15.0%) vs. Postop 36 (13.9%), p = .719)., Conclusion: Initiating thromboprophylaxis preoperatively may reduce the incidence of postoperative VTE without affecting the incidence of posthepatectomy haemorrhage in patients undergoing liver resection., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
12. Outcomes and quality of life after major bile duct injury in long-term follow-up.
- Author
-
Koppatz H, Sallinen V, Mäkisalo H, and Nordin A
- Subjects
- Bile Ducts surgery, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Bile Duct Diseases, Quality of Life
- Abstract
Introduction: Recently new standards for reporting outcomes of bile duct injury (BDI) have been proposed. It is unclear how these treatment outcomes are reflected in quality of life (QOL). The aim of this study was to report outcomes and QOL after repair of major BDI and compare repairs by hepatobiliary surgeon to repairs by non-hepatobiliary surgeons., Methods: This was a retrospective study of patients treated for major (Strasberg E-type) BDI after cholecystectomy at a tertiary hepatobiliary center. Outcomes were assessed using Cho-Strasberg proposed standards. QOL was assessed using Short Form Health Survey (SF-36) and the gastrointestinal QOL-index (GIQLI). Patients undergoing uneventful cholecystectomy matched by age, urgency, and duration of follow-up were used as controls., Results: Fifty-two patients with major BDI treated between 2000 and 2016 were included (42% male, median age 53 years). Thirty-seven (71%) patients attained primary patency (29 (83%) if primarily operated by a hepatobiliary surgeon). Actuarial primary patency rate (grade A result) at 1, 3, and 5 years was 58%, 56%, and 53% in the whole cohort, and 83%, 80%, and 80% in patients primary treated by a hepatobiliary surgeon, respectively. At 3-year follow-up 6 (11.5%) patients obtained grade B, 10 (19.2%) grade C, and 7 (13.5%) grade D result. QOL was similar in patients with BDI and controls (median SF-36 physical component 51.7 and 53.6, p = 1.0, mental component 53.3 and 53.4, p = 1.0, GIQLI 109.0 and 123.0, p = 0.174, respectively) at median 90 (IQR 70-116) months from cholecystectomy. QOL was similar regardless of outcome grade., Conclusion: First attempt to repair a severe BDI should be undertaken by a hepatobiliary surgeon. However, long-term QOL is not affected even by severe BDI, and QOL is not associated with the grade of the outcome.
- Published
- 2021
- Full Text
- View/download PDF
13. Long-term Morbidity of Choledochal Malformations in Children.
- Author
-
Hyvärinen I, Hukkinen M, Kivisaari R, Parviainen H, Mäkisalo H, Koivusalo A, and Pakarinen M
- Subjects
- Bile Ducts, Intrahepatic, Child, Female, Follow-Up Studies, Humans, Male, Morbidity, Postoperative Complications epidemiology, Postoperative Complications etiology, Retrospective Studies, Choledochal Cyst diagnostic imaging, Choledochal Cyst epidemiology
- Abstract
Objective: The aim of the study was to assess long-term morbidity in children operated for choledochal malformation (CM) by relating clinical complications to liver histopathology, follow-up imaging, liver stiffness, and biochemistry., Methods: A single-center retrospective follow-up study including all CM patients (n = 55, 71% girls) treated during 1976 to 2018 was performed. Mann-Whitney U test and Spearman rank correlation were used for statistical analyses., Results: During median follow-up of 5.8 (interquartile range, 2.5-12) years, 1 patient was lost to follow-up whereas all survived. Intraoperative liver biopsies showed fibrosis in 32%, and patients with Metavir stage ≥2 were younger at surgery (0.36 [0.11-1.9] vs 3.8 [0.72-10.5] years, P = 0.024) than those without fibrosis. Overall, 21% had long-term complications including cholangitis in 9 (>2 episodes in 5) patients, anastomotic stricture in 2 referred patients and adhesive volvulus or hepatocellular carcinoma in 1 each. Anastomotic strictures were successfully managed nonoperatively and hepatocellular carcinoma with thermoablation. In postoperative magnetic resonance cholangiography (MRCP) performed 6.4 (3.6-16) years after hepaticojejunostomy, diameters of both main intrahepatic ducts had decreased significantly to 3.0 (2.5-3.5) mm (P = 0.0001) but a distal cyst stump was remaining in 30% with a length of 6.0 (4.0-20) mm that associated with operation age (r = 0.71, P = 0.015) and fusiform CM type. Follow-up ultrasound revealed mild dilation of intrahepatic bile ducts in 6.3% and mildly to moderately elevated liver biochemistry in 23%, and liver stiffness (>7 kPa) in 22%., Conclusions: Whilst cholangitis was the most common postoperative problem, individual patients experienced other more significant complications and one quarter of patients showed evidence of underlying liver dysfunction., Competing Interests: The authors report no conflicts of interest., (Copyright © 2021 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
- Published
- 2021
- Full Text
- View/download PDF
14. A randomized, controlled trial comparing the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in adult liver transplant recipients.
- Author
-
Eriksson M, Käyhty H, Lahdenkari M, Mäkisalo H, and Anttila VJ
- Subjects
- Adult, Antibodies, Bacterial, Humans, Pneumococcal Vaccines adverse effects, Polysaccharides, Vaccination, Vaccines, Conjugate, Liver Transplantation, Pneumococcal Infections prevention & control
- Abstract
Background: Solid organ transplant (SOT) patients are at significant risk for invasive pneumococcal disease. The optimal pneumococcal vaccination strategy for SOT patients is not known., Methods: The potential adult liver transplant recipients were randomised into two arms: to receive a 23-valent pneumococcal polysaccharide vaccine (PPV23) before the transplantation or to receive a 13-valent pneumococcal conjugate vaccine (PCV13) before the transplantation and a second dose of PCV13 six months after the transplantation. Serotype-specific antibody concentrations and opsonophagocytic activity (OPA) were measured before and after the first vaccination (visits V1,V2) and six and seven months after the transplantation, e.g. before and after the second PCV13 (visits V3,V4)., Results: Out of 47 patients, 19 (PCV13 arm) and 17 (PPV23 arm) received a liver transplant and all these patients completed the study (36/47, 76,6%). Each vaccine schedule elicited a good immune response. At V2, the geometric mean concentrations (GMĆs) of antibodies for serotypes 6A, 7F and 23F, and the geometric mean titers (GMT́s) of OPA for serotypes 4, 6A, 6B and 23F were significantly higher for PCV13, but the proportions of patients reaching OPA cut-off ≥ 8 or ELISA cut-off ≥ 1.0 µg/ml did not differ between the arms. At V3 the antibody concentrations and the OPA had declined to baseline in both arms. The second PCV13 vaccination elicited an immune response. There was no difference in adverse events. No vaccine-related allograft rejection was detected., Conclusions: The immunogenicity of PPV23 and PCV13 was comparable in this patient material, but the seroresponses waned after transplantation. The second dose of PCV13 restored the immune responses and was well tolerated., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
15. The Association of Time to Organ Procurement on Short- and Long-Term Outcomes in Kidney Transplantation.
- Author
-
Eerola V, Helanterä I, But A, Lempinen M, Mäkisalo H, Nordin A, Isoniemi H, and Sallinen V
- Subjects
- Adult, Female, Finland, Humans, Male, Middle Aged, Retrospective Studies, Time Factors, Treatment Outcome, United States, Kidney Transplantation, Time-to-Treatment statistics & numerical data, Tissue and Organ Procurement statistics & numerical data
- Abstract
Background and Objectives: Transplant centers in Europe aim to minimize the time from brain death to organ procurement (procurement delay), but evidence to justify this is scarce. In the United States, procurement times are significantly longer. Our objective was to analyze how procurement delay associates with kidney allograft outcomes., Design, Setting, Participants, & Measurements: Kidney transplantations from brain-dead donors were retrospectively analyzed from the Finnish Kidney Transplant Registry and the Scientific Registry of Transplant Recipients in the United States. Multivariable models were adjusted with donor and recipient characteristics, and the relationship between procurement delay and outcomes was modeled with cubic spline functions., Results: In total, 2388 and 101,474 kidney transplantations in Finland and the United States were included, respectively. The median procurement delay was 9.8 hours (interquartile range, 7.8-12.4) in Finland and 34.8 hours (interquartile range, 26.3-46.3) in the United States. A nonlinear association was observed between procurement delay and the risk of delayed graft function, with highest risk seen in short and very long procurement delays. In multivariable models, the lowest risk of delayed graft function was associated with procurement delay between 20 and 50 hours. In multivariable models, longer procurement delay was linearly associated with lower risk of graft loss (hazard ratio, 0.90/1 h longer; 95% confidence interval, 0.88 to 0.92; P <0.001). Acute rejection rates, for which data were only available from Finland, were not associated with procurement delay., Conclusions: Longer procurement delay was associated with noninferior or even better kidney allograft outcomes., (Copyright © 2021 by the American Society of Nephrology.)
- Published
- 2021
- Full Text
- View/download PDF
16. Randomised sham-controlled double-blind trial evaluating remote ischaemic preconditioning in solid organ transplantation: a study protocol for the RIPTRANS trial.
- Author
-
Uutela A, Helanterä I, Lemström K, Passov A, Syrjälä S, Åberg F, Mäkisalo H, Nordin A, Lempinen M, and Sallinen V
- Subjects
- Double-Blind Method, Humans, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Ischemic Preconditioning, Organ Transplantation, Reperfusion Injury prevention & control
- Abstract
Introduction: Remote ischaemic preconditioning (RIPC) using a non-invasive pneumatic tourniquet is a potential method for reducing ischaemia-reperfusion injury. RIPC has been extensively studied in animal models and cardiac surgery, but scarcely in solid organ transplantation. RIPC could be an inexpensive and simple method to improve function of transplanted organs. Accordingly, we aim to study whether RIPC performed in brain-dead organ donors improves function and longevity of transplanted organs., Methods and Analyses: RIPTRANS is a multicentre, sham-controlled, parallel group, randomised superiority trial comparing RIPC intervention versus sham-intervention in brain-dead organ donors scheduled to donate at least one kidney. Recipients of the organs (kidney, liver, pancreas, heart, lungs) from a randomised donor will be included provided that they give written informed consent. The RIPC intervention is performed by inflating a thigh tourniquet to 300 mm Hg 4 times for 5 min. The intervention is done two times: first right after the declaration of brain death and second immediately before transferring the donor to the operating theatre. The sham group receives the tourniquet, but it is not inflated. The primary endpoint is delayed graft function (DGF) in kidney allografts. Secondary endpoints include short-term functional outcomes of transplanted organs, rejections and graft survival in various time points up to 20 years. We aim to show that RIPC reduces the incidence of DGF from 25% to 15%. According to this, the sample size is set to 500 kidney transplant recipients., Ethics and Dissemination: This study has been approved by Helsinki University Hospital Ethics Committee and Helsinki University Hospital's Institutional Review Board. The study protocol was be presented at the European Society of Organ Transplantation congress in Copenhagen 14-15 September 2019. The study results will be submitted to an international peer-reviewed scientific journal for publication., Trial Registration Number: NCT03855722., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
17. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
- Author
-
Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullières O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Mäkisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy A, Scholz T, Settmacher U, Soliman T, Strasser S, Söderdahl G, Troisi RI, Turrión VS, Schlitt HJ, and Geissler EK
- Subjects
- Aged, Carcinoma, Hepatocellular mortality, Female, Humans, Intention to Treat Analysis, Liver Neoplasms mortality, Male, Middle Aged, Survival Rate, Carcinoma, Hepatocellular surgery, Immunosuppressive Agents therapeutic use, Liver Neoplasms surgery, Liver Transplantation mortality, Neoplasm Recurrence, Local prevention & control, Sirolimus therapeutic use
- Abstract
Objective: The aim of this study was to evaluate the survival benefit of sirolimus in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC) (exploratory analysis of the SiLVER-trial)., Summary and Background Data: Patients receiving LT) for HCC are at a high risk for tumor recurrence. Calcineurin inhibitors have shown evidence to promote cancer growth, whereas mammalian target of rapamycin (mTOR) inhibitors like sirolimus have anticancer effects. In the SiLVER-trial (Clinicaltrials.gov: NCT00355862), the effect of sirolimus on the recurrence of HCC after LT was investigated in a prospective randomized trial. Although the primary endpoint of improved disease-free survival (DFS) with sirolimus was not met, outcomes were improved for patients in the sirolimus-treatment arm in the first 3 to 5 years. To learn more about the key variables, a multivariate analysis was performed on the SiLVER-trial data., Patients and Methods: Data from 508 patients of the intention-to-treat analysis were included in exploratory univariate and multivariate models for overall survival (OS), DFS and a competing risk analysis for HCC recurrence., Results: Sirolimus use for ≥3 months after LT for HCC independently reduced the hazard for death in the multivariate analysis [hazard ratio (HR): 0.7 (95% confidence interval, CI: 0.52-0.96, P = 0.02). Most strikingly, patients with an alpha-fetoprotein (AFP) ≥10 ng/mL and having used sirolimus for ≥3 months, benefited most with regard to OS, DFS, and HCC-recurrence (HR: 0.49-0.59, P = 0.0079-0.0245)., Conclusions: mTOR-inhibitor treatment with sirolimus for ≥3 months improves outcomes in LT for HCC, especially in patients with AFP-evidence of higher tumor activity, advocating particularly for mTOR inhibitor use in this subgroup of patients., Clinical Trial Registration: EudraCT: 2005-005362-36 CLINICALTRIALS.GOV:: NCT00355862.
- Published
- 2020
- Full Text
- View/download PDF
18. Predictors of insufficient recanalization and portal hypertensive complications after treatment of non-cirrhotic, non-malignant portal vein thrombosis - a population-based study.
- Author
-
Lemma A, Åberg F, Mäkisalo H, Vikatmaa P, Mentula P, Leppäniemi A, and Sallinen V
- Subjects
- Acute Disease, Anticoagulants therapeutic use, Humans, Liver Cirrhosis complications, Liver Cirrhosis pathology, Portal Vein pathology, Retrospective Studies, Treatment Outcome, Pancreatitis pathology, Thrombosis
- Abstract
Objectives: In acute portal vein thrombosis (PVT), a six-month anticoagulation treatment achieves complete recanalization in only 35%-45% of patients, but the predictors of poor treatment responses are unclear. We examined treatment outcomes in PVT and aimed to identify predictors of incomplete recanalization and portal hypertensive complications., Materials and Methods: This retrospective study comprised patients diagnosed with PVT between 2006 and 2015. Key exclusion criteria were liver cirrhosis, malignancy, and age <18., Results: The final cohort comprised 145 patients, of whom 132 (92%) were primarily treated with anticoagulation. The 5-year cumulative incidence of complete recanalization was 42% and of portal hypertensive complications, 31%. Independent predictors of insufficient recanalization were sub-acute or chronic thrombosis (hazard ratio (HR) 3.1, 95% CI 1.6-5.8), while acute pancreatitis was a protective factor (HR 0.3, 95% CI 0.2 - 0.7). Independent predictors of incident portal hypertensive complications were as cites at baseline (HR 3.3, 95% CI 1.7-6.7), sub-acute or chronic thrombosis (HR 2.9, 95% CI 1.6-5.3), extension of thrombosis to the splenic or mesenteric vein (HR 2.6, 95% CI 1.2-5.7), myeloproliferative disease (HR 3.0, 95% CI 1.4-6.5), and anemia (HR 2.1, 95% 1.1-3.9), while acute pancreatitis was a protective factor (HR 0.1, 95% CI 0.03-0.5)., Conclusions: Etiology and age of thrombosis are associated with treatment responses in PVT. The presence of ascites at baseline, etiology, and extent of thrombosis, a non-acute thrombosis and anemia, are associated with the risk of portal hypertensive complications. Etiology and extent of thrombosis should be taken into account when determining the treatment (method) for PVT.
- Published
- 2020
- Full Text
- View/download PDF
19. Corrigendum to: L-Cysteine Containing Vitamin Supplement Which Prevents or Alleviates Alcohol-related Hangover Symptoms: Nausea, Headache, Stress and Anxiety.
- Author
-
Eriksson CJP, Metsälä M, Möykkynen T, Mäkisalo H, Kärkkäinen O, Palmén M, Salminen JE, and Kauhanen J
- Published
- 2020
- Full Text
- View/download PDF
20. L-Cysteine Containing Vitamin Supplement Which Prevents or Alleviates Alcohol-related Hangover Symptoms: Nausea, Headache, Stress and Anxiety.
- Author
-
Eriksson CJP, Metsälä M, Möykkynen T, Mäkisalo H, Kärkkäinen O, Palmén M, Salminen JE, and Kauhanen J
- Subjects
- Adult, Alcoholic Intoxication complications, Alcoholic Intoxication diagnosis, Anxiety diagnosis, Anxiety etiology, Dietary Supplements, Double-Blind Method, Headache diagnosis, Headache etiology, Humans, Male, Middle Aged, Nausea diagnosis, Nausea etiology, Young Adult, Alcoholic Intoxication drug therapy, Anxiety drug therapy, Cysteine administration & dosage, Headache drug therapy, Nausea drug therapy, Vitamins administration & dosage
- Abstract
Aims: Alcohol-related hangover symptoms: nausea, headache, stress and anxiety cause globally considerable amount of health problems and economic losses. Many of these harmful effects are produced by alcohol and its metabolite, acetaldehyde, which also is a common ingredient in alcohol beverages. The aim of the present study is to investigate the effect of the amino acid L-cysteine on the alcohol/acetaldehyde related aftereffects., Methods: Voluntary healthy participants were recruited through advertisements. Volunteers had to have experience of hangover and/or headache. The hangover study was randomized, double-blind and placebo-controlled. Nineteen males randomly swallowed placebo and L-cysteine tablets. The alcohol dose was 1.5 g/kg, which was consumed during 3 h., Results: The primary results based on correlational analysis showed that L-cysteine prevents or alleviates hangover, nausea, headache, stress and anxiety. For hangover, nausea and headache the results were apparent with the L-cysteine dose of 1200 mg and for stress and anxiety already with the dose of 600 mg., Conclusions: L-cysteine would reduce the need of drinking the next day with no or less hangover symptoms: nausea, headache, stress and anxiety. Altogether, these effects of L-cysteine are unique and seem to have a future in preventing or alleviating these harmful symptoms as well as reducing the risk of alcohol addiction., (© The Author(s) 2020. Medical Council on Alcohol and Oxford University Press. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
21. Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.
- Author
-
Goeppert B, Folseraas T, Roessler S, Kloor M, Volckmar AL, Endris V, Buchhalter I, Stenzinger A, Grzyb K, Grimsrud MM, Gornicka B, von Seth E, Reynolds GM, Franke A, Gotthardt DN, Mehrabi A, Cheung A, Verheij J, Arola J, Mäkisalo H, Eide TJ, Weidemann S, Cheville JC, Mazza G, Hirschfield GM, Ponsioen CY, Bergquist A, Milkiewicz P, Lazaridis KN, Schramm C, Manns MP, Färkkilä M, Vogel A, Boberg KM, Schirmacher P, and Karlsen TH
- Subjects
- Adolescent, Adult, Aged, Bile Duct Neoplasms mortality, Bile Duct Neoplasms pathology, Bile Duct Neoplasms therapy, Child, Cholangiocarcinoma mortality, Cholangiocarcinoma pathology, Cholangiocarcinoma therapy, Cyclin-Dependent Kinase Inhibitor p16 genetics, Female, Genes, p53, Genomics, Humans, Male, Middle Aged, Mutation, Proto-Oncogene Proteins p21(ras) genetics, Young Adult, Bile Duct Neoplasms genetics, Cholangiocarcinoma genetics, Cholangitis, Sclerosing complications
- Abstract
Background and Aims: Lifetime risk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and BTC is currently the leading cause of death in patients with PSC. To open new avenues for management, we aimed to delineate clinically relevant genomic and pathological features of a large panel of PSC-associated BTC (PSC-BTC)., Approach and Results: We analyzed formalin-fixed, paraffin-embedded tumor tissue from 186 patients with PSC-BTC from 11 centers in eight countries with all anatomical locations included. We performed tumor DNA sequencing at 42 clinically relevant genetic loci to detect mutations, translocations, and copy number variations, along with histomorphological and immunohistochemical characterization. Regardless of the anatomical localization, PSC-BTC exhibited a uniform molecular and histological characteristic similar to extrahepatic cholangiocarcinoma. We detected a high frequency of genomic alterations typical of extrahepatic cholangiocarcinoma, such as TP53 (35.5%), KRAS (28.0%), CDKN2A (14.5%), and SMAD4 (11.3%), as well as potentially druggable mutations (e.g., HER2/ERBB2). We found a high frequency of nontypical/nonductal histomorphological subtypes (55.2%) and of the usually rare BTC precursor lesion, intraductal papillary neoplasia (18.3%)., Conclusions: Genomic alterations in PSC-BTC include a significant number of putative actionable therapeutic targets. Notably, PSC-BTC shows a distinct extrahepatic morpho-molecular phenotype, independent of the anatomical location of the tumor. These findings advance our understanding of PSC-associated cholangiocarcinogenesis and provide strong incentives for clinical trials to test genome-based personalized treatment strategies in PSC-BTC., (© 2020 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of American Association for the Study of Liver Diseases.)
- Published
- 2020
- Full Text
- View/download PDF
22. A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.
- Author
-
Eriksson M, Käyhty H, Saha H, Lahdenkari M, Koskinen P, Mäkisalo H, and Anttila VJ
- Subjects
- Adult, Aged, Double-Blind Method, Female, Humans, Immunization, Secondary, Male, Middle Aged, Pneumococcal Vaccines administration & dosage, Renal Dialysis, Transplant Recipients, Antibodies, Bacterial blood, Immunogenicity, Vaccine, Kidney Transplantation adverse effects, Pneumococcal Vaccines immunology
- Abstract
Background: The risk of invasive pneumococcal disease is significant among solid organ transplant (SOT) recipients. The optimal pneumococcal vaccination strategy for SOT patients is not known., Methods: The potential kidney transplant recipients in dialysis were randomized into two arms: to receive a 23-valent pneumococcal polysaccharide vaccine (PPV23) before transplantation or to receive a 13-valent pneumococcal conjugate vaccine (PCV13) before transplantation and a second dose of PCV13 six months after the transplantation. Serotype-specific antibody concentrations and opsonophagocytic activity (OPA) were measured before and after the first vaccination (visits V1,V2) and six and seven months after the transplantation, for example, before and after the second PCV13 (visits V3,V4)., Results: Out of 133 participants, 48 (PCV13 arm) and 46 (PPV23 arm) received a kidney transplant, and 37 + 37 in both arms completed the study. After the first vaccination, the geometric mean concentrations (GMCs) in the PCV13 arm were significantly higher for 9/13 serotypes and the OPA geometric mean titers (GMTs) were significantly higher for 4/13 serotypes. At V3, the antibody levels had declined but OPA remained significantly higher for 7/13 (PCV13) vs 4/13 (PPV23) serotypes. At V4, the GMCs for 9/13 serotypes and the GMTs for 12/13 serotypes were significantly higher in the PCV13 arm. The GMCs but not GMTs were lower than at V2. There was no difference in adverse effects. No vaccine-related allograft rejection was detected., Conclusions: The immunogenicity of PCV13 was better in dialysis patients, and revaccination with PCV13 was immunogenic and safe., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
23. Incidence and long-term outcomes of surgically treated childhood hepatic malignancies in Finland.
- Author
-
Tiusanen T, Hukkinen M, Leskinen O, Soini T, Kanerva JA, Jahnukainen T, Mäkisalo H, Heikinheimo M, and Pakarinen MP
- Subjects
- Aged, Child, Child, Preschool, Finland epidemiology, Humans, Incidence, Infant, Treatment Outcome, Hepatoblastoma drug therapy, Hepatoblastoma epidemiology, Hepatoblastoma surgery, Liver Neoplasms epidemiology, Liver Neoplasms surgery, Liver Transplantation
- Abstract
Aim: To analyse incidence, treatment and outcomes of paediatric liver malignancies in Finland during 1987-2017., Methods: Medical records and national cancer registry data of 47 children with liver malignancies were reviewed. Survival was calculated with the Kaplan-Meier method., Results: During follow-up, liver malignancy incidence remained stable at 1.1:10
6 . Altogether, 42 patients with hepatoblastoma (n = 24), hepatocellular carcinoma (n = 11) and undifferentiated embryonal sarcoma (n = 7) underwent surgery at median age 4.6 (interquartile range, 2.0-9.6) years and were followed up for 13 (7.0-19) years. Cumulative 5-year survival was 86% for hepatoblastoma, 41% for hepatocellular carcinoma and 67% for undifferentiated embryonal sarcoma. Five-year survival was decreased among hepatoblastoma patients aged ≥ 2.4 years (73% versus 100%, P = .040), with PRETreatment EXTent of disease IV (PRETEXT, 60% vs 100%, P = .004), and with recurrent disease (67% vs 88%, P = .029). Recurrent/residual disease associated with decreased 5-year survival in hepatocellular carcinoma (0% vs 83%, P = .028). Survival was similar among 19 transplanted and 23 resected patients. In total, 14 deaths occurred either for the underlying malignancy (n = 8), adverse effects of chemotherapy (n = 5) or unrelated reasons (n = 1)., Conclusion: Outcomes for PRETEXT I-III hepatoblastoma and un-metastasized hepatocellular carcinoma were encouraging. Adverse effects of chemotherapy significantly contributed to mortality., (©2019 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.)- Published
- 2020
- Full Text
- View/download PDF
24. Graft glycocalyx degradation in human liver transplantation.
- Author
-
Passov A, Schramko A, Mäkisalo H, Nordin A, Andersson S, Pesonen E, and Ilmakunnas M
- Subjects
- Adult, Aged, Glycocalyx pathology, Humans, Liver pathology, Middle Aged, Reperfusion Injury pathology, Glycocalyx metabolism, Heparitin Sulfate metabolism, Liver metabolism, Liver Transplantation, Reperfusion Injury metabolism, Syndecan-1 metabolism
- Abstract
Objective: Ischaemia/reperfusion-injury degrades endothelial glycocalyx. Graft glycocalyx degradation was studied in human liver transplantation., Methods: To assess changes within the graft, blood was drawn from portal and hepatic veins in addition to systemic samples in 10 patients. Plasma syndecan-1, heparan sulfate and chondroitin sulfate, were measured with enzyme-linked immunosorbent assay., Results: During reperfusion, syndecan-1 levels were higher in graft caval effluent [3118 (934-6141) ng/ml, P = 0.005] than in portal venous blood [101 (75-121) ng/ml], indicating syndecan-1 release from the graft. Concomitantly, heparan sulfate levels were lower in graft caval effluent [96 (32-129) ng/ml, P = 0.037] than in portal venous blood [112 (98-128) ng/ml], indicating heparan sulfate uptake within the graft. Chondroitin sulfate levels were equal in portal and hepatic venous blood. After reperfusion arterial syndecan-1 levels increased 17-fold (P < 0.001) and heparan sulfate decreased to a third (P < 0.001) towards the end of surgery., Conclusion: Syndecan-1 washout from the liver indicates extensive glycocalyx degradation within the graft during reperfusion. Surprisingly, heparan sulfate was taken up by the graft during reperfusion. Corroborating previous experimental reports, this suggests that endogenous heparan sulfate might be utilized within the graft in the repair of damaged glycocalyx., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
25. Transcatheter arterial embolization in hepatic tumor hemorrhage.
- Author
-
Nykänen T, Peltola E, Sallinen V, Mäkisalo H, Nordin A, Kylänpää L, and Udd M
- Subjects
- Adult, Aged, Aged, 80 and over, Blood Transfusion, Carcinoma, Hepatocellular complications, Carcinoma, Hepatocellular mortality, Computed Tomography Angiography, Female, Finland, Gastrointestinal Hemorrhage etiology, Gastrointestinal Hemorrhage mortality, Hospital Mortality, Humans, Liver Neoplasms complications, Liver Neoplasms mortality, Male, Middle Aged, Prognosis, Retrospective Studies, Time Factors, Treatment Outcome, Carcinoma, Hepatocellular therapy, Embolization, Therapeutic methods, Gastrointestinal Hemorrhage therapy, Liver Cirrhosis complications, Liver Neoplasms therapy
- Abstract
Objective: Spontaneous hepatic tumor hemorrhage is a rare but challenging emergency especially among cirrhotic patients with poor hepatic function. This study aimed at analyzing the safety, efficacy and feasibility of transcatheter arterial embolization (TAE) in the treatment of hepatic tumor hemorrhage. Methods: This retrospective study included all patients undergoing embolization attempt for hepatic tumor hemorrhage in the Helsinki University Hospital during 2004-2017. Electronic medical records provided the study data. Outcomes included the 30-day rebleeding, complication and mortality rates, need for blood transfusions, durations of intensive care unit and hospital admissions, estimates of overall survival, and analysis of factors associated with 30-day mortality. Results: During the study period, 49 patients underwent angiography for hepatic tumor hemorrhage. TAE was technically feasible in 45 patients (92%), and controlled the bleeding with the first attempt in 84%. The 30-day complication and mortality rates were 57 and 33%, respectively. Major complications occurred in 33% of patients. In-hospital mortality was higher among cirrhotic than non-cirrhotic patients (55 versus 7%, p < .001). Patients with bleeding hepatic metastases, but no cirrhosis, had an in-hospital mortality of 0% with no major complications. Patients with benign etiology had a good prognosis and no bleeding- or tumor-related mortality. Discussion: TAE is an effective method in controlling the bleeding in spontaneous hepatic hemorrhage. Underlying pathology determines the prognosis that is poor especially in cirrhotic patients with bleeding hepatocellular carcinoma.
- Published
- 2019
- Full Text
- View/download PDF
26. Cutavirus DNA in Malignant and Nonmalignant Skin of Cutaneous T-Cell Lymphoma and Organ Transplant Patients but Not of Healthy Adults.
- Author
-
Väisänen E, Fu Y, Koskenmies S, Fyhrquist N, Wang Y, Keinonen A, Mäkisalo H, Väkevä L, Pitkänen S, Ranki A, Hedman K, and Söderlund-Venermo M
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Viral blood, Biopsy, Cohort Studies, Cyclohexanecarboxylic Acids blood, Female, Healthy Volunteers, Humans, Immunocompromised Host, Male, Middle Aged, Organ Transplantation, Skin pathology, Skin Neoplasms pathology, Young Adult, DNA, Viral isolation & purification, Lymphoma, T-Cell, Cutaneous virology, Parvovirinae, Skin virology, Skin Neoplasms virology, Transplant Recipients
- Abstract
Background: Three new parvoviruses of Protoparvovirus genus, bufavirus (BuV), tusavirus (TuV), and cutavirus (CuV), have recently been discovered in diarrheal stools. CuV was further detected in a proportion of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides skin samples and in one melanoma., Patients and Methods: With novel multiplex quantitative polymerase chain reaction and antibody assays, we studied 3 patient groups for BuV, TuV, and CuV DNA and immunoglobulin G (IgG): CTCL patients, immunosuppressed solid-organ transplant recipients, and immunocompetent healthy adults., Results: CuV DNA was detected in skin biopsies of 4/25 (16.0%) CTCL and 4/136 (2.9%) transplant patients but not in any of 159 skin samples of 98 healthy adults. The dermal CuV-DNA prevalence was significantly higher in CTCL patients than in the other subjects. CuV DNA was further detected in healthy skin of 4 organ transplant recipients, 2 of whom also had CuV-positive skin carcinomas. One CTCL patient harbored CuV DNA in both malignant (CTCL, melanoma) and nonmalignant skin and sentinel lymph nodes but not in his prostate. The CuV IgG seroprevalences were among CTCL patients 9.5% (4/42), transplant recipients 6.5% (8/124), and healthy adults 3.8% (3/78). BuV and TuV DNAs were absent and antibodies infrequent in all cohorts. Parvoviral antibodies were shown to persist for ≥20 years and dermal CuV DNA for 4 years. All 3 CuV-DNA-positive patients, with both biopsies and sera available, were CuV-IgG positive., Conclusion: Our results suggest that dermal CuV DNA carriage is associated with CTCL. Any putative roles of CuV in the carcinogenesis must be determined in forthcoming studies., (© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
27. Occurrence of newly discovered human polyomaviruses in skin of liver transplant recipients and their relation with squamous cell carcinoma in situ and actinic keratosis - a single-center cohort study.
- Author
-
Wang Y, Keinonen A, Koskenmies S, Pitkänen S, Fyhrquist N, Sadeghi M, Mäkisalo H, Söderlund-Venermo M, and Hedman K
- Subjects
- Adult, Aged, Biopsy, Carcinoma, Squamous Cell complications, Carcinoma, Squamous Cell virology, Cohort Studies, End Stage Liver Disease complications, Female, Humans, Keratosis, Actinic complications, Keratosis, Actinic virology, Male, Middle Aged, Skin immunology, Skin Neoplasms complications, Skin Neoplasms virology, End Stage Liver Disease surgery, Liver Transplantation, Polyomavirus isolation & purification, Polyomavirus Infections virology, Skin virology, Tumor Virus Infections virology
- Abstract
To date 14 human polyomaviruses (HPyVs) have been identified. The newly found HPyVs have not been examined with regard to post-transplant skin carcinogenesis. To determine the occurrences in skin and possible pathological associations of the HPyVs, we studied their genoprevalences in squamous cell carcinoma (SCC) in situ or actinic keratosis and benign skin in liver transplant recipients (LiTRs); and of healthy skin in immunocompetent adults. We used highly sensitive and specific HPyV PCRs of two types. Overall, Merkel cell polyomavirus (MCPyV), human polyomavirus 6 (HPyV6), human polyomavirus 7 (HPyV7), trichodysplasia spinulosa polyomavirus (TSPyV), and Lyon IARC polyomavirus (LIPyV) were found in 58/221 (26.2%) skin biopsies. MCPyV DNA was detected in 5/14 (35.7%) premalignant vs. 32/127 (25.2%) benign skin of LiTRs, and in 12/80 (15%) healthy skin of immunocompetent adults, with no statistically significant difference in viral DNA prevalence or load. TSPyV DNA was found in a single skin lesion. LIPyV, HPyV6 and HPyV7 DNAs occurred exclusively in benign skin. Overall, the viral findings in premalignant versus benign skin were alike. The occurrences of HPyVs in skin of LiTRs and immunocompetent individuals speak against a role for any of the 14 HPyVs in SCC development., (© 2019 Steunstichting ESOT.)
- Published
- 2019
- Full Text
- View/download PDF
28. The Helsinki approach to face transplantation.
- Author
-
Lindford AJ, Mäkisalo H, Jalanko H, Lauronen J, Anttila VJ, Juteau S, Ämmälä AJ, Eskola A, Saarni S, Isoniemi H, Mäkitie A, and Lassus P
- Subjects
- Adult, Algorithms, Finland, Humans, Male, Middle Aged, Patient Care Team economics, Patient Care Team ethics, Patient Care Team legislation & jurisprudence, Treatment Outcome, Facial Transplantation, Patient Care Team organization & administration
- Abstract
Aim: We herein describe the establishment of the Helsinki Vascularized Composite Allotransplantation (VCA) program and its execution in the first two face transplant cases., Methods & Patients: The Helsinki VCA program initially required the fulfillment of legal, hospital, financial, and ethical requirements. Thereafter, the assembling of a multidisciplinary team commenced. A team of Plastic, maxillofacial and ENT surgeons comprise the facial VCA team. The protocol involves collaboration with the Solid Organ Transplant (SOT) team, transplant immunology, immunosuppression, microbiology, psychiatric evaluation, well-defined VCA indications and informed consent. Between 2011 and 2017 two patients were selected for transplantation. Both patients had a severe composite facial deformity involving the maxilla and mandible following earlier ballistic injury., Results: Patient 1 was a 35 year-old male who underwent successful near total face transplantation in February 2016 and at 30 months he has a good aesthetic outcome with symmetrical restoration of the central face and good sensory and symmetrical motor functional outcomes. Patient 2 was a 58 year-old male who underwent full face transplantation in March 2018 and at 5 months he has recovered without major problems., Conclusion: A successful facial VCA program requires a well-prepared research protocol, experts from multiple specialties and careful patient selection. The establishment of the Helsinki VCA program required long and thorough planning and resulted in the first two Nordic face transplantation cases. This protocol now forms the platform (as a proof of concept) for other types of vascularized composite allotransplantations., (Copyright © 2018 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
29. Severe allograft rejection in an intestinal transplant patient following oral immunoglobulin treatment for chronic norovirus infection: a case report.
- Author
-
Åberg F, Savikko J, Anttila VJ, and Mäkisalo H
- Abstract
In an intestinal transplant patient under triple immunosuppression therapy with tacrolimus levels >10 ng/L, a 2-day oral immunoglobulin therapy given as treatment for chronic norovirus infection was temporally closely associated with the development of severe steroid-resistant acute graft rejection, thus suggesting that oral immunoglobulin might be able to promote a rejection response.
- Published
- 2018
- Full Text
- View/download PDF
30. Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis.
- Author
-
Boyd S, Vannas M, Jokelainen K, Isoniemi H, Mäkisalo H, Färkkilä MA, and Arola J
- Subjects
- Adult, Age Factors, Bile Duct Neoplasms diagnostic imaging, Bile Duct Neoplasms etiology, Bile Duct Neoplasms surgery, Bile Ducts pathology, Biopsy, CA-19-9 Antigen blood, Cholangiocarcinoma diagnostic imaging, Cholangiocarcinoma etiology, Cholangiocarcinoma surgery, Cholangiopancreatography, Endoscopic Retrograde, Cholangitis, Sclerosing complications, Cholangitis, Sclerosing diagnostic imaging, Cholangitis, Sclerosing surgery, Early Detection of Cancer methods, Female, Humans, Liver Function Tests, Male, Middle Aged, Time Factors, Bile Duct Neoplasms pathology, Biomarkers, Tumor blood, Cholangiocarcinoma pathology, Cholangitis, Sclerosing pathology, Liver Transplantation
- Abstract
Aim: To investigate markers for high-grade dysplasia for the optimal timing of liver transplantation in patients with primary sclerosing cholangitis (PSC)., Methods: Earlier data support a dysplasia-carcinoma sequence, even low- to high-grade dysplasia, in PSC-associated cholangiocarcinoma (CCA). Surveillance using endoscopic retrograde cholangiography (ERC) and brush cytology aims to detect cases of biliary dysplasia, and liver transplantation is an option in cases with suspicion of malignancy in brushing. This study investigated markers to identify patients with high-grade biliary dysplasia for optimal timing in early liver transplantation. Patients undergoing surveillance using ERC and brush cytology during 2008-2014 and who were diagnosed with biliary dysplasia in explanted liver or CCA until February 2016 were included in the study. Demographic data, cholangiography findings, laboratory values, cytological morphology and DNA ploidy were analysed., Results: Thirty PSC patients had biliary neoplasia in the explanted liver during the study period. Sixteen of these patients had low-grade dysplasia, 10 patients had high-grade dysplasia, and 4 patients had CCA. Fifteen PSC patients diagnosed with CCA were not transplanted. Patients with low-grade dysplasia were younger. Alkaline phosphatase or carcinoembryonic antigen values did not differ between groups during surveillance, but carbohydrate antigen 19-9 was higher in CCA patients. No difference in PSC duration, ERC scores, suspicious cytology, or ploidy analysis was found between groups. No difference was observed between fibrosis stage in explanted livers. Low- and high-grade dysplasia could not be differentiated before liver transplantation based on liver enzymes, tumour markers, ERC scores, brush cytology or DNA ploidy., Conclusion: Repeated suspicion of neoplasia in brush cytology should be an indication for evaluations of liver transplantation prior to the development of CCA., Competing Interests: Conflict-of-interest statement: We have no financial relationships to disclose.
- Published
- 2017
- Full Text
- View/download PDF
31. Liver trauma in a young woman.
- Author
-
Saarinen T and Mäkisalo H
- Subjects
- Animals, Blood Transfusion, Female, Fluid Therapy, Horses, Humans, Resuscitation methods, Young Adult, Accidental Falls, Conservative Treatment, Liver injuries
- Abstract
A young woman fell off a horse, leaving her right flank contused by a hoof. This resulted in a severe liver trauma that seemed to require surgical treatment. After fluid resuscitation and five units of red blood cells the patient's status, however, stabilized upon entering the operating room. The operation was avoided, but intensive care follow-up was continued for six days. The patient made a complete recovery. Conservative treatment of liver trauma is successful in 90% of mild and almost 70% in severe traumas.
- Published
- 2017
32. Post-transplant Merkel Cell Carcinoma.
- Author
-
Koljonen V, Sahi H, Böhling T, and Mäkisalo H
- Subjects
- Carcinoma, Merkel Cell epidemiology, Carcinoma, Merkel Cell therapy, Host-Parasite Interactions, Humans, Polyomavirus immunology, Polyomavirus pathogenicity, Risk Assessment, Risk Factors, Skin Neoplasms epidemiology, Skin Neoplasms therapy, Skin Neoplasms virology, Treatment Outcome, Carcinoma, Merkel Cell immunology, Carcinoma, Merkel Cell virology, Immunocompromised Host, Immunosuppressive Agents adverse effects, Organ Transplantation adverse effects, Skin Neoplasms immunology
- Abstract
Malignant tumours are the foremost complications of immunosuppressive treatment. They are a major challenge for organ transplant recipients and their treating physicians. This paper reviews the aetiology and current treatment of an unusual neuroendocrine skin cancer, Merkel cell carcinoma (MCC), caused by a Merkel cell polyomavirus infection. MCC occurs more frequently than expected in immunosuppressed subjects, especially in organ transplant recipients. The current literature comprises reports of 79 organ transplant recipients with MCC. The risk of MCC in organ transplant recipients is increased up to 66-182-fold compared with the general population. In addition to the increased risk of developing MCC, immunosuppressed individuals have poorer MCC-specific survival. The aim of this review article is to familiarize organ transplant doctors with this unique and clinically challenging skin cancer, and to provide recent data on the diagnosis and current treatment recommendations for an immunosuppressed population.
- Published
- 2016
- Full Text
- View/download PDF
33. Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients.
- Author
-
Kivelä JM, Kosola S, Peräsaari J, Mäkisalo H, Jalanko H, Holmberg C, Pakarinen MP, and Lauronen J
- Subjects
- Adolescent, Child, Child, Preschool, Cross-Sectional Studies, Female, Follow-Up Studies, Graft Rejection immunology, Graft Survival immunology, Histocompatibility Testing, Humans, Infant, Inflammation, Male, Prevalence, Research Design, Histocompatibility Antigens Class II immunology, Isoantibodies blood, Liver Transplantation adverse effects
- Abstract
The role of donor-specific HLA antibodies (DSAs) after pediatric liver transplantation (LT) is inadequately established. We conducted a cross-sectional study on the prevalence of DSAs and their association with liver histology and biochemical variables after pediatric LT. Serum samples were drawn for HLA antibody analyses from 50 patients (76% of 66 eligible patients) operated on at age <18 years between 1987 and 2007 with a median of 10.0 (interquartile range 4.0-16.4) years after deceased donor LT. Mixed and single-antigen beads with Luminex were used for HLA antibody screening and detection. A mean fluorescence intensity (MFI) value of 1000 was used for positive cutoff. Twenty-six patients (52%; 95% confidence interval (CI) 39% to 65%) had DSAs. In 22 (85%) patients, DSAs were against class II HLA antigens with a mean (standard deviation) MFI of 13,481 (4727). The unadjusted prevalence ratio for portal inflammation in DSA-positive compared to DSA-negative patients (n = 47; 9/24 vs. 1/23) was 8.6 (95% CI 1.6 to 50.9). Laboratory values at the time of study were comparable between DSA-positive and DSA-negative patients. In conclusion, approximately half of patients studied had DSAs after pediatric LT. Portal inflammation was associated with DSA positivity although the wide confidence interval around the ratio estimate warrants cautious interpretation., (© 2016 Steunstichting ESOT.)
- Published
- 2016
- Full Text
- View/download PDF
34. [Prophylactic platelet transfusions].
- Author
-
Ilmakunnas M, Remes K, Hiippala S, Mäkisalo H, and Åberg F
- Subjects
- Finland, Hemorrhage etiology, Humans, Platelet Aggregation Inhibitors adverse effects, Thrombocytopenia complications, Thrombocytopenia therapy, Hemorrhage prevention & control, Platelet Transfusion statistics & numerical data, Surgical Procedures, Operative
- Abstract
The consumption of platelet products in Finland is exceptionally high. For the most part, platelets are transfused pre-operatively to thrombocytopenic patients in order to prevent hemorrhage. Most of the minor procedures could, however, be conducted even if the patients'platelet levels would be lower than usual. In cardiac surgery, platelets are used because of the hemorrhagic diathesis associated with platelet inhibitors. Platelet inhibitors will, however, also bind to transfused platelets, whereby instead of prophylactic platelet transfusions it would be more sensible to leave the thorax open and not carry out ineffective platelet transfusions until the effect of the inhibitors has run out. We outline the prophylactic use of platelets based on recent international clinical practice guidelines.
- Published
- 2016
35. What to do when I find a focal lesion in the liver?
- Author
-
Mäkisalo H and Lantto E
- Subjects
- Biopsy, Diagnosis, Differential, Humans, Liver Neoplasms pathology, Magnetic Resonance Imaging, Neoplasm Metastasis, Liver Neoplasms diagnosis
- Abstract
A focal lesion in a healthy liver of a person not having cancer is almost always benign. Diagnosis is often achieved on the basis of anamnesis and imaging findings. A histologic specimen is required in the case of suspected malignant tumor or hepatocellular adenoma. Magnetic resonance imaging is the primary investigation for an unresolved focal lesion of a cancer patient, and the histologic specimen will, when necessary, be taken only after this. Early detection of metastases of colorectal cancer in particular is important, since metastases that have spread to the liver or lungs may be operable. A focal lesion in a cirrhotic liver is either a regenerative nodule or hepatocellular carcinoma.
- Published
- 2016
36. [Dangerous animals].
- Author
-
Koljonen V, Söderlund T, Mäkisalo H, and Gissler M
- Subjects
- Accidents, Traffic, Animals, Finland epidemiology, Hospitalization statistics & numerical data, Humans, Wounds and Injuries epidemiology, Horses, Wounds and Injuries etiology
- Abstract
Contacts between humans and animals inevitably involve encounters possibly resulting in the human being injured. During the period of 2000 to 2014 almost 90 people died in this kind of conflict in Finland. Of these deaths, one third were associated with horses. In addition, over the same period 85 people died in traffic accidents in which an animal was hit by a car. Accidents requiring hospitalization occurred for approx. 8 000 people.
- Published
- 2016
37. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
- Author
-
Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrión VS, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, and Schlitt HJ
- Subjects
- Adult, Age Factors, Aged, Australia, Canada, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Disease Progression, Disease-Free Survival, Drug Therapy, Combination, Europe, Female, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Liver Neoplasms mortality, Liver Neoplasms pathology, Male, Middle Aged, Neoplasm Recurrence, Local, Prospective Studies, Risk Assessment, Risk Factors, TOR Serine-Threonine Kinases antagonists & inhibitors, TOR Serine-Threonine Kinases metabolism, Time Factors, Treatment Outcome, Young Adult, Carcinoma, Hepatocellular surgery, Immunosuppressive Agents therapeutic use, Liver Neoplasms surgery, Liver Transplantation adverse effects, Liver Transplantation mortality, Sirolimus therapeutic use
- Abstract
Background: We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC)., Methods: In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overall survival (OS) was a secondary endpoint., Results: Recurrence-free survival was 64.5% in group A and 70.2% in group B at study end, this difference was not significant (P = 0.28; hazard ratio [HR], 0.84; 95% confidence interval [95% CI], 0.62; 1.15). In a planned analysis of RFS rates at yearly intervals, group B showed better outcomes 3 years after transplantation (HR, 0.7; 95% CI, 0.48-1.00). Similarly, OS (P = 0.21; HR, 0.81; 95% CI, 0.58-1.13) was not statistically better in group B at study end, but yearly analyses showed improvement out to 5 years (HR, 0.7; 95% CI, 0.49-1.00). Interestingly, subgroup (Milan Criteria-based) analyses revealed that low-risk, rather than high-risk, patients benefited most from sirolimus; furthermore, younger recipients (age ≤60) also benefited, as well sirolimus monotherapy patients. Serious adverse event numbers were alike in groups A (860) and B (874)., Conclusions: Sirolimus in LTx recipients with HCC does not improve long-term RFS beyond 5 years. However, a RFS and OS benefit is evident in the first 3 to 5 years, especially in low-risk patients. This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC.
- Published
- 2016
- Full Text
- View/download PDF
38. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
- Author
-
Lautenschlager I, Loginov R, Mäkisalo H, and Höckerstedt K
- Subjects
- Adult, DNA, Viral blood, Ganciclovir therapeutic use, Humans, Incidence, Longitudinal Studies, Plasma virology, Prospective Studies, Real-Time Polymerase Chain Reaction, Valganciclovir, Antiviral Agents therapeutic use, Chemoprevention methods, Cytomegalovirus Infections epidemiology, Cytomegalovirus Infections prevention & control, Ganciclovir analogs & derivatives, Liver Transplantation, Transplant Recipients
- Abstract
Background: Cytomegalovirus (CMV) can cause severe infections in transplanted patients. To prevent CMV infection, most liver centers use prophylaxis for CMV-seronegative recipients receiving an organ from a seropositive donor (D+/R-). Valganciclovir is mostly given for 3-6 months after transplantation. However, the patients may develop primary CMV infection after the cessation of prophylaxis and late-onset CMV disease may occur., Objectives: A prospective long-term follow-up of CMV (D+/R-) adult liver transplant recipients after 3 months valganciclovir prophylaxis was investigated., Study Design: Of 154 consecutive adult liver recipients transplanted from 2006 to 2009, 20 (13%) were CMV D+/R- and received antiviral prophylaxis up to 3 months after transplantation. After excluding the recipients with incomplete prophylaxis or monitoring, 13 (D+/R-) patients with follow-up of >4 years after the 3-month period of valganciclovir prophylaxis were included in the study.The patients were monitored for CMV by real-time quantitative plasma PCR., Results: No break-through CMV infections were recorded during the prophylaxis period. After cessation of valganciclovir prophylaxis 12/13 (90%) patients demonstrated CMV-DNAemia following a post transplantation mean interval of 165 days (range 95-320). Ten patients with high viral loads (peak viral load mean 81,510, range 1900-648950cps/ml) were successfully treated, 6 with valganciclovir, and 4 with ganciclovir. Two patients with low level CMV-DNAemia (<1000cps/ml) were asymptomatic and not treated. No intragraft infection was seen, but one patient developed gastrointestinal CMV infection verified from ileum biopsy. During long-term follow-up, 3 patients demonstrated low-level viral replication, but no symptomatic recurrences occurred. One patient died of bacterial sepsis, but no patient or graft was lost due to CMV., Conclusions: Primary CMV infections after cessation of prophylaxis were common, but were successfully treated with valganciclovir or ganciclovir., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
39. Self-reported alcohol use and depressive symptoms after liver transplantation.
- Author
-
Koljonen V, Åberg F, Rovasalo A, and Mäkisalo H
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Alcohol Abstinence psychology, Alcohol Drinking adverse effects, Alcohol Drinking epidemiology, Biomarkers blood, Biomarkers urine, Cross-Sectional Studies, Depression diagnosis, Depression epidemiology, Female, Finland epidemiology, Health Behavior ethnology, Health Knowledge, Attitudes, Practice, Humans, Liver Diseases diagnosis, Liver Diseases epidemiology, Liver Diseases psychology, Liver Diseases, Alcoholic epidemiology, Liver Diseases, Alcoholic psychology, Liver Diseases, Alcoholic surgery, Liver Transplantation adverse effects, Male, Middle Aged, Prevalence, Prospective Studies, Risk Factors, Sex Factors, Time Factors, Treatment Outcome, Young Adult, Alcohol Drinking psychology, Depression psychology, Liver Diseases surgery, Liver Transplantation psychology, Self Report
- Abstract
Background: The prevalence of alcohol use among Finnish liver transplant recipients has not been studied before., Methods: We used self-report questionnaires and correlations between alcohol use liver biochemistry and depressive symptoms at the only transplant unit of the country, during a 6-month period in 2013., Results: The final study population consisted of 207 recipients. After verbal consent, participants filled in Alcohol Use Disorder Identification Test C and Beck Depression Inventory-II. Twenty percent of patients had been transplanted because of alcoholic liver disease. Of the patients, 43% reported alcohol use any time after liver transplantation (LT) and 28% during the past 1 month. Nearly all of those who received LT during childhood reported alcohol use more often and more drinks per occasion. Statistically significant risk factors for harmful drinking were male sex, age younger than 18 years at transplantation, and years from transplantation. Neither cause nor the depression scores reached statistical significance. Alcohol users had statistically significant higher liver biochemistry markers., Conclusion: Our results revealed a 43% overall use of alcohol after LT and 28% use of alcohol within the last month and low depression scores. Among participants with alcohol liver disease origin, 39% and 34% any time and during the past 1 month, respectively, reported relapse. The alcohol consumption revealed in this study is similar to that of the general alcohol consumption tradition in Finland. Young males transplanted during their childhood were at most risk for harmful drinking.
- Published
- 2015
- Full Text
- View/download PDF
40. Fifteen years' experience of intestinal and multivisceral transplantation in the Nordic countries.
- Author
-
Varkey J, Simrén M, Jalanko H, Oltean M, Saalman R, Gudjonsdottir A, Gäbel M, Borg H, Edenholm M, Bentdal O, Husby S, Staun M, Mäkisalo H, Bosaeus I, Olausson M, Pakarinen M, and Herlenius G
- Subjects
- Adolescent, Adult, Aged, Cause of Death, Child, Child, Preschool, Female, Graft Survival, Humans, Liver Transplantation, Male, Middle Aged, Parenteral Nutrition, Postoperative Complications, Scandinavian and Nordic Countries, Young Adult, Graft Rejection drug therapy, Graft vs Host Disease drug therapy, Immunosuppressive Agents therapeutic use, Intestinal Diseases therapy, Intestines transplantation
- Abstract
Objective: Intestinal and multivisceral transplantation have gained acceptance as treatment modalities for patients with: intestinal failure and life-threatening complications of parenteral nutrition (PN), rare cases of vascular abdominal catastrophes and selected cases of low-grade neoplastic tumors such as neuroendocrine pancreatic tumors and desmoids involving the mesenteric root. The aim was to describe the survival and nutritional outcome in the transplanted Nordic patients and the complications attributed to this procedure., Method: The authors included all Nordic patients transplanted between January 1998 and December 2013. Information on patients transplanted outside the Nordic region was collected through questionnaires., Results: A total of 34 patients received different types of intestinal allografts. Currently, there are two Nordic transplant centers (n = 29) performing these procedures (Gothenburg, Sweden n = 24, Helsinki, Finland n = 5). The remaining five patients were transplanted in the USA (n = 3) and the UK (n = 2). Most patients were transplanted for life-threatening failure of PN (70%) caused primarily by intestinal motility diseases (59%). Allograft rejection was the most common complication and occurred in 79% of the patients followed by post-transplantation lymphoproliferative disorders (21%) and graft-versus-host disease (18%). The 1- and 5-year survival was 79% and 65% respectively for the whole cohort and nutritional autonomy was achieved in 73% of the adults and 57% of the children at 1 year after transplantation., Conclusion: This collective Nordic experience confirms that intestinal transplantation is a complex procedure with many complications, yet with the possibility to provide long-term survival in selected conditions previously considered untreatable.
- Published
- 2015
- Full Text
- View/download PDF
41. Surgical rehabilitation of short and dysmotile intestine in children and adults.
- Author
-
Hukkinen M, Merras-Salmio L, Sipponen T, Mutanen A, Rintala RJ, Mäkisalo H, and Pakarinen MP
- Subjects
- Adolescent, Adult, Bilirubin blood, Biopsy, Child, Child, Preschool, Cholestasis physiopathology, Digestive System Surgical Procedures methods, Female, Humans, Infant, Liver Cirrhosis physiopathology, Male, Parenteral Nutrition, Total, Retrospective Studies, Survival, Treatment Outcome, Young Adult, Intestines physiopathology, Intestines transplantation, Short Bowel Syndrome rehabilitation, Short Bowel Syndrome surgery
- Abstract
Aims: This is a descriptive study aiming to compare outcomes of intestinal rehabilitation surgery among pediatric and adult intestinal failure (IF) patients with either primary intestinal motility disorders or short bowel syndrome (SBS) treated by our nationwide program., Methods: Medical records of IF patients (n = 31, 71% children) having undergone autologous intestinal reconstructions (AIR) (n = 25), intestinal transplantation (ITx) (n = 5), or being listed for ITx (n = 2) between 1994 and 2014 were reviewed., Results: At surgery, median age was 3.4 (interquartile range, 1.0-22.1) in SBS (n = 22) and 16.5 (3.2-26.7) years in dysmotility patients (n = 9) who received median 60% and 83% of energy requirement parenterally, respectively. Median small bowel length was shorter in SBS than dysmotility patients (34 versus 157 cm, p < 0.001). Following AIR, none of the dysmotility patients achieved permanent intestinal autonomy, whereas 68% of SBS patients weaned off parenteral nutrition (PN) (p = 0.022) and none required listing for ITx. Five dysmotility patients who underwent ITx achieved intestinal autonomy. Regarding both AIR and ITx procedures, no significant difference in PN weaning was observed between the two subgroups. At last follow-up, 3.3 (0.6-8.0) years postoperatively, median plasma bilirubin was 6 (4-16) µmol/l, while liver biopsy showed fibrosis (Metavir stage 1-2) in 50% and cholestasis in 8%. Proportion of PN energy requirement had reduced significantly (p = 0.043) among PN-dependent SBS (n = 7) but not among dysmotility patients (n = 5). Overall survival was 90%., Conclusion: AIR surgery was beneficial among selected SBS patients, whereas in intestinal dysmotility disorders, permanent PN weaning was only achieved by ITx.
- Published
- 2015
- Full Text
- View/download PDF
42. Who is too healthy and who is too sick for liver transplantation: external validation of prognostic scores and survival-benefit estimation.
- Author
-
Åberg F, Nordin A, Mäkisalo H, and Isoniemi H
- Subjects
- Adolescent, Adult, Aged, Female, Finland, Graft Survival, Humans, Logistic Models, Male, Middle Aged, Prognosis, Severity of Illness Index, Survival Rate, Treatment Outcome, Waiting Lists, Young Adult, Liver Diseases therapy, Liver Transplantation mortality, Patient Selection, Transplant Recipients
- Abstract
Objective: Thresholds for when a patient should be considered too healthy or too sick to undergo liver transplantation (LT) have been pursued, but have undergone little external validation and may differ between centers and countries., Material and Methods: We investigated the ability of the Model for End-stage Liver Disease (MELD), D-MELD, Donor Risk Index (DRI) and Balance of Risk (BAR) scores to predict 1-year graft survival, and determined the 1-year survival-benefit of LT, compared with conservative management, according to MELD score and graft quality among 538 adult LT recipients with underlying chronic non-malignant liver disease., Results: One-year graft survival rates showed small, but statistically significant variation according to MELD (p = 0.002) and D-MELD score (p = 0.04), and among LTs after year 2000 also according to BAR score (p = 0.01), but not according to DRI. Diagnostic accuracy of these scores was poor; area under the curve was 0.50-0.65 depending on the score. A 1-year survival-benefit of LT emerged at MELD scores ≥15, but also at lower MELD scores when using high-quality grafts (DRI <1.075)., Conclusions: The performance of various prognostic scores in the Finnish setting was poor. Careful clinical evaluation is imperative when deciding on the timing of LT in the course of chronic liver disease.
- Published
- 2015
- Full Text
- View/download PDF
43. [Chronic liver disease and thrombosis risk].
- Author
-
Aberg F, Lassila R, Ilmakunnas M, Jokelainen K, Numminen K, and Mäkisalo H
- Subjects
- Algorithms, Blood Coagulation Disorders complications, Blood Coagulation Disorders drug therapy, Chronic Disease, Humans, Prognosis, Risk Factors, Anticoagulants therapeutic use, Liver Cirrhosis complications, Portal Vein, Portasystemic Shunt, Transjugular Intrahepatic, Venous Thrombosis etiology, Venous Thrombosis therapy
- Abstract
The coagulopathy of chronic liver disease involves elevated risks for thrombosis in the portal vein and extra-splanchic sites. Hypercoagulability may moreover accelerate liver fibrosis progression. Cirrhosis-related portal vein thrombosis is associated with decompensation events and inferior prognosis; anticoagulation therapy achieves complete recanalization in -40% of recent thromboses and prevents thrombosis progression in chronic cases. Standard thrombosis prophylaxis seems appropriate for hospitalized cirrhotic patients. This review provides practical guidance to tailoring anticoagulation therapy in cirrhosis according to individual bleeding risk. We also propose an algorithm for using anticoagulation and transjugular intrahepatic portosystemic shunts in the treatment of cirrhotic portal vein thrombosis.
- Published
- 2015
44. Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation.
- Author
-
Hynynen J, Komulainen T, Tukiainen E, Nordin A, Arola J, Kälviäinen R, Jutila L, Röyttä M, Hinttala R, Majamaa K, Mäkisalo H, and Uusimaa J
- Subjects
- Adolescent, Adult, DNA Polymerase gamma, DNA, Mitochondrial metabolism, Fatal Outcome, Female, Humans, Liver drug effects, Liver metabolism, Liver pathology, Liver Failure, Acute genetics, Liver Failure, Acute surgery, Male, Mutation, Retrospective Studies, Transplants pathology, Young Adult, Anticonvulsants adverse effects, DNA-Directed DNA Polymerase genetics, Liver Failure, Acute chemically induced, Liver Transplantation, Valproic Acid adverse effects
- Abstract
Patients with mutations in the POLG1 gene encoding mitochondrial DNA polymerase gamma have an increased risk of valproate-induced liver failure. POLG1 mutations are common, and these patients often suffer from intractable seizures. The role of liver transplantation in the treatment of patients with mitochondrial diseases has been controversial. We studied valproate-induced liver failure associated with POLG1 mutations and the prognosis for these patients after liver transplantation. POLG1 was analyzed in blood DNA, mitochondrial DNA (mtDNA) was quantified in liver samples, and clinical data were collected. Five patients with valproate-induced liver failure associated with POLG1 mutations were retrospectively identified. Three patients were previously suspected to have Wilson's disease. Four patients with homozygous p.W748S and p.E1143G mutations had mtDNA depletion in the liver. One of these patients died before anticipated transplantation; the other 3 patients with liver transplantation have survived 4 to 19 years. Two patients have presented with occasional epileptic seizures, and 1 patient has been seizure-free for 11 years. One patient with a heterozygous p.Q1236H mutation (but without mtDNA depletion in the liver) died suddenly 2 years after liver transplantation. In conclusion, the POLG1 mutation status and the age at presentation of valproate-induced liver failure can affect the prognosis after liver transplantation. A heterozygous POLG1 p.Q1236H mutation was related to valproate-induced liver failure without mtDNA depletion, whereas patients homozygous for POLG1 p.W748S and p.E1143G mutations had mtDNA depletion. An analysis of the POLG1 gene should be performed for all patients with suspected mitochondrial disease before the introduction of valproate therapy, and treatment with valproic acid should be avoided in these patients., (© 2014 American Association for the Study of Liver Diseases.)
- Published
- 2014
- Full Text
- View/download PDF
45. Liver transplant in siblings--a single center experience.
- Author
-
Koljonen VS and Mäkisalo HH
- Subjects
- Adolescent, Adult, Aged, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular surgery, Child, Child, Preschool, End Stage Liver Disease epidemiology, End Stage Liver Disease pathology, End Stage Liver Disease surgery, Female, Finland, Humans, Liver Cirrhosis, Biliary genetics, Liver Cirrhosis, Biliary surgery, Liver Neoplasms pathology, Liver Neoplasms surgery, Male, Middle Aged, Prevalence, Recurrence, Retrospective Studies, Sepsis physiopathology, Young Adult, Liver Transplantation methods, Siblings
- Published
- 2014
- Full Text
- View/download PDF
46. Neutrophil gelatinase-associated lipocalin associated with irreversibility of pre-liver transplant kidney dysfunction.
- Author
-
Aberg F, Lempinen M, Hollmén M, Nordin A, Mäkisalo H, and Isoniemi H
- Subjects
- Acute Kidney Injury blood, Acute Kidney Injury therapy, Acute-Phase Proteins, Adult, Female, Follow-Up Studies, Glomerular Filtration Rate, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents therapeutic use, Kidney Function Tests, Lipocalin-2, Liver Diseases blood, Male, Middle Aged, Prognosis, Prospective Studies, Renal Replacement Therapy, Risk Factors, Acute Kidney Injury diagnosis, Biomarkers blood, Lipocalins blood, Liver Diseases surgery, Liver Transplantation, Proto-Oncogene Proteins blood
- Abstract
Kidney outcomes in early post-liver transplantation (LT) are crucial for long-term prognosis, but difficult to predict. Among 203 adult LT patients, we studied the value of plasma neutrophil gelatinase-associated lipocalin (NGAL) measured pre-LT for predicting acute kidney injury (AKI), kidney-replacement therapy within three months, and kidney dysfunction at three months post-LT. Glomerular filtration rate (GFR) was estimated by creatinine-based and cystatin C-based equations. Highest NGAL levels were among patients on pre-LT kidney-replacement therapy, whereas NGAL exceeded 200 μg/L in only three (2%) patients with pre-LT GFR >60 mL/min. Pre-LT NGAL >260 μg/L predicted GFR <60 mL/min at three months post-LT (OR 17.8, 95% CI 2.1-153) independently of 19 other variables reflecting recipient characteristics, liver and kidney function, perioperative hemodynamic stress, and immunosuppression. Of 81 patients with pre-LT GFR <60 mL/min, 48% had GFR <60 mL/min at three months, and an NGAL level >260 μg/L predicted this outcome with 90% specificity and 46% sensitivity. NGAL failed to predict post-LT AKI or need for temporary kidney-replacement therapy. In conclusion, NGAL independently predicted irreversibility of pre-LT kidney dysfunction and could thus help in optimizing patient care and in the decision to perform combined liver-kidney transplantation. Pre-LT NGAL was not useful in patients with preserved pre-LT kidney function or in predicting post-LT AKI., (© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
47. Late hepatic artery thrombosis after pediatric liver transplantation: a cross-sectional study of 34 patients.
- Author
-
Kivelä JM, Kosola S, Kalajoki-Helmiö T, Mäkisalo H, Jalanko H, Holmberg C, Pakarinen MP, and Lauronen J
- Subjects
- Adolescent, Angiography, Child, Child, Preschool, Cross-Sectional Studies, Female, Graft Survival, Humans, Liver pathology, Magnetic Resonance Imaging, Male, Retrospective Studies, Risk Factors, Ultrasonography, Hepatic Artery physiopathology, Liver Failure surgery, Liver Transplantation, Thrombosis physiopathology
- Abstract
Hepatic artery thrombosis (HAT) after liver transplantation (LT) increases patient morbidity and mortality. Early HAT is considered to occur within the first month after LT, whereas late HAT occurs after the first month. Few studies have addressed late HAT after LT, especially in pediatric patients. Between 1987 and 2007, 99 patients (age < 18 years) underwent deceased donor LT. Thirty-four of 66 eligible patients (52%) underwent magnetic resonance imaging (MRI) according to protocol. On the basis of MRI findings, the patients were grouped as those who experienced late HAT and those who did not. Additionally, potential risk factors for late HAT were analyzed retrospectively. P values were adjusted for multiplicity. The median age at LT was 1.7 years [interquartile range (IQR) = 1.0-9.6 years], and the median follow-up time at MRI was 9.5 years (IQR = 4.0-16.4 years). Late HAT was diagnosed in 15 of the 34 patients [44%, 95% confidence interval (CI) = 29%-61%] undergoing MRI and in 3 of these patients with angiography preceding MRI. Ultrasonography revealed late HAT in 6 of these 15 patients with a sensitivity of 40% (95% CI = 20%-64%). The donor/recipient weight ratio remained significantly higher for the patients with late HAT versus the patients without late HAT after P values were adjusted (5.4 versus 1.9, P = 0.03). No marked differences were observed in laboratory or liver histology parameters between the groups. In conclusion, late HAT is common after pediatric LT. The donor/recipient weight ratio was higher for patients with late HAT, and this was attributable to the lower weight of the recipients. No salient features of late HAT were observed with respect to laboratory or histological parameters, at least in terms of our study's cross-sectional period., (© 2014 American Association for the Study of Liver Diseases.)
- Published
- 2014
- Full Text
- View/download PDF
48. [Parenteral nutrition--temporary and permanent treatment].
- Author
-
Bäcklund M and Mäkisalo H
- Subjects
- Aged, Energy Intake, Humans, Nutrition Disorders diet therapy, Parenteral Nutrition methods
- Abstract
Enteral nutrition of an elderly patient having ended up in hospital or intensive care and suffering from malnutrition should be started as soon as it is technically possible. If less than 60% of the estimated energy need is fulfilled during the first week of treatment, parenteral nutrition should also be initiated. Multi-chamber bags are the most effective means to provide energy and nutrients via the central vein. To reduce the risk of liver damage, parenteral nutrition is upon prolongation recommended to be administered periodically. Weight monitoring is important in order to observe the effect of the treatment and the possible accumulation of fluid load.
- Published
- 2014
49. [Cytology is in pivotal role at screening and surveillance of PSC].
- Author
-
Boyd S, Arola J, Mäkisalo H, and Färkkilä M
- Subjects
- Bile Duct Neoplasms pathology, Bile Duct Neoplasms prevention & control, Bile Ducts, Intrahepatic, Cholangiocarcinoma pathology, Cholangiocarcinoma prevention & control, Cholangiopancreatography, Endoscopic Retrograde, Cholangitis, Sclerosing epidemiology, Cholangitis, Sclerosing pathology, Cholangitis, Sclerosing therapy, Finland epidemiology, Flow Cytometry, Humans, Liver Transplantation, Population Surveillance, Cholangitis, Sclerosing diagnosis, Cytological Techniques methods
- Abstract
Primary sclerosing cholangitis (PSC) is an autoimmune disease leading to biliary strictures and inflammation. The lifetime risk for cholangiocarcinoma (CCA) among PSC patients is 7-13%, and biliary dysplasia is thought to be a precursor lesion for CCA. The diagnosis of PSC is based on endoscopic retrogradic cholangiography (ERC). During ERC brush cytology samples are routinely taken in our unit to detect possible biliary dysplasia. With repeated cytological dysplasia, liver transplantation is considered. Aneuploidy in DNA flow cytometry may support the suspicion of dysplasia. PSC is the most common indication for liver transplantation in Finland, and half of transplantations are prophylactic.
- Published
- 2014
50. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma.
- Author
-
Lempinen M, Lyytinen I, Nordin A, Tervahartiala T, Mäkisalo H, Sorsa T, and Isoniemi H
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Enzyme-Linked Immunosorbent Assay, Female, Finland, Fluoroimmunoassay, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Prognosis, Retrospective Studies, Time Factors, Young Adult, Carcinoma, Hepatocellular pathology, Liver Neoplasms pathology, Matrix Metalloproteinase 8 blood, Matrix Metalloproteinase 9 blood, Tissue Inhibitor of Metalloproteinase-1 blood
- Abstract
Aim: Prediction of prognosis in hepatocellular carcinoma (HCC) is difficult. The aim of this study was to evaluate the prognostic value of serum MMP-8, -9, -13, and TIMP-1 in patients with HCC., Methods: Pre-treatment serum samples from 134 patients with HCC were retrospectively analyzed. The serum concentration of MMP-8 was analyzed with immunofluorometric assay (IFMA), and those of MMP-9, MMP-13, and TIMP-1 were determined by enzyme-linked immunosorbent assays (ELISA). Clinical data were retrieved from patient records and survival data obtained from Statistics Finland., Results: The overall cumulative disease-specific survival was 69% at 1 year, 50% at 2 years, and 33% at 5 years. Kaplan-Meier overall survival analysis showed that patients with low concentrations of serum MMP-8 or TIMP-1 had a statistically significantly better overall survival than patients with high concentrations of serum MMP-8 or TIMP-1 (P=0.013 and P=0.003). Interestingly, the overall survival in patients with high MMP-9/TIMP-1 ratio was statistically significantly better than in those patients with low MMP-9/TIMP-1 ratio (P=0.004)., Conclusion: Our results suggest that serum MMP-8, TIMP-1, and the ratio of MMP-9/TIMP-1 might be useful adjuncts as predictors of prognosis in patients with HCC.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.